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The relevance of the “carbonyl approach”—the concise
term for the use of [M(OH2)3(CO)3]+ (M=99mTc, 188Re)
for the labeling of biomolecules—is the subject of con-
tinuing controversy. This commentary presents argu-
ments in favor of the carbonyl approach, mainly based
on chemical considerations. “New approaches are not es-
sential” and “what is available already satisfies our
needs” are quite frequent objections to application of the
carbonyl approach. It is redundant to comment on this,
since any reasonable and worthwhile approach will con-
tribute in extending the scientific horizons of a research
field. Ultimately, the innovations offered by researchers
and market demand will decide the utility of a novel con-
cept.
With the introduction of the “Isolink” kit (Mallinck-
rodt Medical B.V.), it has become feasible to comple-
ment the radiopharmaceutical research armamentarium
with an organometallic moiety as an additional powerful
tool. Thus, the complex [99mTc(OH2)3(CO)3]+ has mutat-
ed from an “exotic organometallic moiety with toxic li-
gands” to a serious, routinely available compound [1].
This progress paves the way for new radiopharmaceuti-
cals both in current research developments and in future
clinical applications.
Arguments for and against a proposition are frequent-
ly complementary. Often, they are ranked from a subjec-
tive standpoint; hence, positive (or negative) arguments
regarding any novel approach first require a general
(subjective) analysis of the actual situation. This analysis
should include future objectives and the rationale for
identifying new targets. In the current context, the limita-
tions of 99mTc-based radiopharmacy need to be consid-
ered, with a view to ascertaining (a) whether there are
persuasive scientific arguments in favor of the carbonyl
approach relative to the established methods and (b)
whether arguments supporting the feasibility of the car-
bonyl approach are sufficient to lead to an impact on
market demand. There is in fact no doubt that 99mTc ra-
diopharmacy needs innovative inputs from chemistry
and not only from biology in order to retain its strong
position vis-à-vis more competitive non-radiodiagnostic
methods. New approaches aiming to improve functional
diagnosis for a variety of diseases and a better under-
standing of physiological processes are inherently attrac-
tive.
Despite enormous efforts worldwide, the number of
FDA-approved 99mTc- and 188Re-labeled vectors is rather
disappointing. One reason for this failure is that, chemi-
cally speaking, a metal complex tagged to a biological
vector is not innocent; in addition, the suitability of the
radiopharmaceutical for routine application may be in-
sufficient to warrant commercial production. The search
for clinically useful and affordable 99mTc- and 188Re-
based compounds relies essentially on the [Tc=O]3+ core,
wrapped by tetradentate NS or NO ligands and covalent-
ly linked to a targeting molecule. These well-established
techniques are complemented to a minor extent by the
mixed ligand [3+1] or the HYNIC approach [2].
Chemical steps in the conventional development of
novel radiopharmaceuticals are outlined in Fig. 1. There
are essentially two aspects to be considered, the prepara-
tion of the precursor and the selection of the ligand. Pre-
cursors such as 111In3+ or Ln3+ form well-defined aquo
ions [M(OH2)n]3+ and do not require cumbersome redox
chemistry, as in the case of [99mTcO4]−. Routine applica-
tion is therefore very convenient. The multitude of po-
tential ligands that may be coordinated to the same core
(and hence the multitude of complexes) allows systemat-
ic screening. Since the metal complex will affect the vec-
tor in a negative or (rarely) a positive way, the more the
physicochemical properties of the metal complex can be
altered, the greater is the chance of finding an ideal can-
didate. Such variation of the metal side in radiopharma-
ceutical chemistry means drug development. This can be
compared to what is carried out with normal pharmaceu-
ticals. The well-established ligands for stabilization of
the [Tc=O]3+ moiety are problematic for varying the
properties of the 99mTc tag since tetra- and tridentate
chelators tend to be synthetically and stereochemically
demanding. Other labeling approaches such as HYNIC
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are more restricted with respect to the vector for which
they are suitable. The arguments supporting the carbonyl
approach discussed later in this commentary refer to
these fundamental considerations.
Accordingly, the situation as depicted in Fig. 1 would
be significantly improved by the existence of an aquo ion
of 99mTc forming stable complexes with a wide variety of
ligands. The more ligand variations are available to coor-
dinate to the metal center along an identical labeling
route, the better are the chances of finding a novel radio-
pharmaceutical. A class of chelators could then be select-
ed matching the physicochemical properties of the vector.
The carbonyl approach (Fig. 2) is in harmony with
both of these requirements as it merges the advantages of
aquo ions (In3+ or Ln3+) with the electronic possibilities
of transition metal ions.
Aquo ions of Tc, desirable but not likely to exist, are
replaced by [99mTc(OH2)3(CO)3]+. This precursor is the
focus of the carbonyl approach and can be called a “semi
aquo ion” with three tightly bound COs and three labile
H2O ligands. This situation compares well with that of
[Ln(aq)]3+; however, the carbonyl approach is more 
favorable since only three coordination sites have to be
considered for ligand design. [99mTc(OH2)3(CO)3]+ rep-
resents a stable, but substitution-reactive precursor with
a d6 electronic configuration. Importantly, as a precursor
it does not necessarily require coligands, as in Tc(V) oxo
species, to stabilize the +I oxidation state, and indepen-
dent of temperature, pH and time, the only product pre-
pared in the kit is [99mTc(OH2)3(CO)3]+. It can be stored
for hours in the kit like a normal 1st row transition metal
aquo ion. Sensitivity at room temperature against O2
is moderate compared with the Tc(V) intermediates.
[99mTc(OH2)3(CO)3]+ is a general precursor for labeling
chemistry (step ii), but it can also be prepared in situ
(step iii), as discussed later. We should not forget at this
point that therapy is the future goal. Radionuclide-based
therapy is not in competition with other non-nuclear
medicine therapeutic methods and can complement che-
motherapy in the treatment of cancer. Synthesis of
[188Re(OH2)3(CO)3]+ is also possible, although it entails
more difficulties, and in contrast to higher oxidation
states, its complexes are more stable than those of
[99mTc(OH2)3(CO)3]+ [3]. The availability of stable ther-
apeutic precursors is a strong argument in favor of the
carbonyl approach. The weakly bound H2O ligands of
[99mTc(OH2)3(CO)3]+ and [188Re(OH2)3(CO)3]+ can be
replaced by essentially any ligand, which leads to a sec-
ond aspect of the carbonyl approach.
The ability to coordinate to multiple ligands is ratio-
nalized by the d6 low spin electron configuration, render-
ing closed shell complexes in an octahedral environment
that are highly robust. It has been argued that kinetic sta-
bility is preferential to thermodynamic stability in com-
pounds related to life science. The most prominent 
example is sestamibi, in which technetium is also in the
+I oxidation state. The Tc–C bond energy would not pre-
vent substitution in physiological media but there is 
simply no reaction pathway of reasonable energy for 
this purpose. The robust nature of the Tc(I) center in
[99mTc(OH2)3(CO)3]+ provides a unique and very high
degree of freedom in selecting the ligands and designing
novel radiopharmaceuticals. The shape of the ligand, the
combination of donors and even denticity are not re-
stricted. Ligands with structures appropriate for particu-
lar biomolecules can be designed “ab initio” based on 
receptor-ligand interactions from molecular modeling
studies. The possibility of designing a complex extends
to modifying an existing framework. The “semi aquo
ion” as a precursor and the formation of robust complex-
es introduce a high degree of diversity in radiopharma-
ceutical research.
This concept has been experimentally verified with
model complexes and labeled biomolecules. Monoden-
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Fig. 1. Steps in the conventional
development of novel radio-
pharmaceuticals: i) reduction,
stabilization with coligands; 
ii) labeling of biomolecule; 
iii) one-step pathway
Fig. 2. Steps in the synthesis of
labeled vectors in the carbonyl
approach
tate ligands such as imidazole or purines, ubiquitous in
biology, bidentate ligands such as histamine, amino ac-
ids, and picolinic acid and tridentate ligands such as his-
tidine efficiently replace the H2O ligands and shield the
[99mTc(CO)3]+ moiety against trans-metallation or reoxi-
dation. The introduction of a linker into the basic ligand
framework or an already present functional group allows
coupling to a biomolecule. Surprisingly, potent ligands,
independently of whether their character is “hard” or
“soft”, span the full range from polyaminopolycarbox-
ylates such as EDTA to agostic hydrides and cyclopenta-
diene. Although even tridentate ligands are not expected
to have high thermodynamic stability constants, all the
model complexes studied so far have shown no decom-
position for days at 37°C in physiological solution and
have been excreted chemically unchanged [4]. Further-
more, the complexes are essentially stable towards reoxi-
dation under aerobic conditions. Synthesis of the com-
plexes does not demand ligand-dependent modifications,
but consists in mixing and, at very low ligand concentra-
tion (<10−5 M), in heating. Thermal stability of the prod-
ucts is a relevant issue for the preparation of radiophar-
maceuticals at high vector dilution. For routine use, the
concentration of receptor targeting molecules in step ii)
or iii) of Fig. 1 or 2 should be low to afford radiophar-
maceuticals of very high specific activity. Such second-
order reactions are slow at low concentrations. The ther-
mal stability of [99mTc(OH2)3(CO)3]+ and the products
allows reactions to be carried out at up to 100°C, accel-
erating the reactions without decomposition of the prod-
ucts. It has been shown that strong (fast) ligands give
reasonable yields, even close to a 99mTc/ligand ratio of
1:1. This favorable coordination chemistry allows the 
selection of ligands from chemical catalogues. In our
own research, we have focused, among others, on triden-
tate histidine for peptides [5] and on cyclopentadiene for
CNS receptor ligands [6], demonstrating the possible
variations. For peptides, hydrophilic amino acid-derived
ligands are suitable, whereas for CNS receptor ligands,
lipophilicity and the molecular weight of the tag 
are important issues. The organometallic nature of
[99mTc(OH2)3(CO)3]+ allows stable occupation of three
coordination sites by a ligand with only five atoms of 
the Cp ring. Considering the core complex only,
[CpTc(CO)3] [7] has a molecular weight of 248 whereas
neutral [TcO(N2S2)] has a molecular weight of 279. Even
smaller ligands can be introduced to further reduce the
molecular weight: 248 is not the lower limit.
Substitution reactions in the carbonyl approach nor-
mally yield a single product even with ligands of a denti-
city less than 3. Mixtures are unlikely since the intermo-
lecular rates are too slow compared with intramolecular
reactions (a consequence of the d6 configuration). One
single direction of the reaction pathway is essential 
in (in)organic medicinal chemistry. Anionic bidentate 
ligands L2, such as imidazole-carboxylic acid, yield 
exclusively [Tc(OH2)(L2)(CO)3] and neutral bidentate 
ligands, [TcCl(L2)(CO)3] [8, 9]. Mixtures of two bi-
dentate ligands (one monodentately bound) have not
been observed. Water in [Tc(OH2)(L2)(CO)3] exchanges 
for an appropriate mononuclear ligand to produce
[Tc(L’1)(L2)(CO)3], leading to a novel mixed ligand
[2+1] concept (Fig. 3). By keeping L2 constant and mod-
ifying L’1 bound to a vector, structure-activity relation-
ships can be systematically studied. Alternatively, the
targeting molecule is bound to L2 and the coligand L’1 is
varied. It has to be emphasized that the precursor
[Tc(OH2)(L2)(CO)3] can be synthesized in one step from
[99mTcO4]−, provided that the ligand is stable against re-
duction. Polarity, charge and (metabolizable) functional
groups can be altered, an essential property for the de-
velopment of radiopharmaceuticals. Once formed, the
[2+1] complexes are extraordinarily stable for hours (i.e.
in boiling saline).
Consequently, the carbonyl approach generally results
in a single, chemically well defined product, this being
essential in order to receive FDA approval. The chemical
form of the complex can be predicted and analytically
confirmed by synthesizing the Re surrogate. Some com-
plexes even give a clear mass signal with ESI-MS at the
99mTc level. The products at the carrier and n.c.a. level
are always identical.
Finally, one-step synthesis of the labeled vector 
directly from [99mTcO4]−, according to pathway iii) in
Fig. 1 or 2, would be preferential for future routine prep-
aration, but this requirement is difficult to fulfill. Where-
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Fig. 3. [2+1] mixed ligand con-
cept for drug development,
with X the ligand to be varied
as the temperature during labeling is often not a critical
issue, the reducing agent may be. Analogous to Sn(II),
boranocarbonate, as used in the preparation of [99mTc
(OH2)3(CO)3]+, can reduce disulfide bonds. However,
under typical reaction conditions amides are not reduced
and biomolecules not susceptible to reduction could be
labeled in a single step from [99mTcO4]−. This is surpris-
ing since stabilization of intermediate valencies such as
Tc(IV) by tridentate ligands, leading to side products,
could be expected but has not been found. Thus, a one-
step reaction for routine application can be achieved, and
kit preparation of a 99mTc labeled vector is feasible.
From a chemical standpoint, the convenience of pre-
paring [99mTc(OH2)3(CO)3]+ in a kit, its clean reaction
with a multitude of free or biomolecule-coupled ligands
at room temperature (10−4 M) or at 100°C (10−6 M) to
yield chemically and biologically stable complexes, and
the possibility of selecting ligands from the bench are the
most important arguments in favor of the carbonyl 
approach. Although discussed in the context of free 
ligands, these properties also apply to chelator-deriva-
tized biomolecules. The carbonyl approach is feasible
and inexpensive and an increasing number of groups
have stepped into this new field. Accepting an organo-
metallic moiety as a versatile precursor seems difficult.
It is essential to recognize that the organometallic nature
of [99mTc(OH2)3(CO)3]+ is the origin of many of the ar-
guments in favor, and coordination compounds may not
exhibit the observed behavior. This fact will hopefully
encourage research into other organometallic cores for
life science. Admittedly, there is still a lack of biological
data to support the value, or even the superiority, of the
carbonyl approach in radiopharmacy. Comparative stud-
ies are required to prove or disprove its complementarity
with the other major labeling techniques. Finally, it
should be emphasized that while to consider the carbonyl
approach as the only solution would be incorrect, its
many advantages, as outlined here, open up novel possi-
bilities.
Regardless of the success of carbonyls in radio-
pharmaceutical chemistry, the research leading to 
[99mTc(OH2)3(CO)3]+ was also recognized by the inorgan-
ic and organometallic community. Procedures introduced
here are likely to be investigated for other transition met-
als as well. It is an unusual situation in which research
from an applied field inspires fundamental chemistry.
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In this commentary we will discuss some of the reasons
why the [Tc(CO)3]+ approach to technetium radiophar-
maceuticals has not obtained a place in the commercial
arena. We do not disagree with the chemical achieve-
ments that were made in preparing bioactive techne-
tium-labeled molecules utilizing the [Tc(CO)3]+ or
[Re(CO)3]+ approach. For example, it is almost a decade
since this approach was used in the synthesis of rheni-
um-labeled estrogen derivatives with high affinity for
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